Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus

Key Takeaways Xenon reported a Q4 loss of $1.31 per share, wider than estimates, with no revenues recorded.XENE's R&D expenses rose 47% to $87.7M, driven by late-stage azetukalner studies.Xenon expects its $586M cash to fund phase III epilepsy, MDD and BPD programs into 2027.Xenon Pharmaceuticals (XENE) reported a loss of $1.31 per share for the fourth quarter of 2025, wider than the Zacks Consensus Estimate of a loss of $1.20. The company had incurred a loss of 84 cents per share in the year-ago quarter.In ...